MD, Oncologist, PhD candidate in Translational Science
📍 Azienda Ospedaliero-Universitaria di Parma
Grant received: €2.900A study of how sex-related genetic and hormonal differences affect the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC). Only ~20% of NSCLC patients gain durable benefit from ICIs: the project looks for sex-specific predictive factors.
This project stems from our group's research on NSCLC and is part of a large prospective study aiming to identify radio-immuno-genomic signatures with prognostic and predictive value for the efficacy of immunotherapy. As a goal of high clinical relevance, we aim to decode the sex-related molecular and immunological bases and determine their implications for the response to immunotherapy in patients with advanced NSCLC.
By integrating clinical, immunophenotypic and genetic-molecular parameters, we aim to identify a sex-specific signature capable of deciphering the immunophenotypic and genomic events that characterise the different clinical outcomes (overall survival and progression-free survival) and treatment response of men and women with advanced NSCLC who are candidates for immunotherapy.
Every €3,000 raised = one more grant in the next call. You run, you donate, they do research.
Donate now See the open call